Lentivirus Infections  >>  Triumeq (dolutegravir/abacavir/lamivudine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
SINGLE, NCT01263015: A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The Trial)

Completed
3
844
US, Canada, Europe, RoW
Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo
ViiV Healthcare, Shionogi, GlaxoSmithKline
Infection, Human Immunodeficiency Virus I
05/12
12/15
NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Active, not recruiting
3
428
US, Canada
ABC/DTG/3TC FDC, Ongoing cART regimen
ViiV Healthcare, PPD, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
04/15
10/15
NCT02105987: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Completed
3
555
US, Canada
ABC/DTG/3TC FDC, Ongoing cART regimen
ViiV Healthcare, PPD, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
04/15
12/15

Download Options